Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-2925 in Fibromyalgia
NCT04147858Phase 2Completed
- Sponsor
- Aptinyx Inc.
- Start
- Nov 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NYX-2925 in fibromyalgia (FM) (3 arms), sponsored by Aptinyx Inc. Primary endpoint: Change in the Mean Numerical Rating Scale Score at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
NYX-2925
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT04147858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04147858.